Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 20, 2018
Pharmacy Choice - News - Pharmaceutical Development - January 20, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

1/20/18 - 3rd Annual Clinical Trial Collaborations Event Comes to Boston in April 2018 [Tehran Times (Iran)]
-The Conference Forum is pleased to announce the launch of the 3rd annual Clinical Trial Collaborations conference in Boston on April 9-11, 2018. Industry veteran, Dr Jeremy Chadwick, Group VP, Clinical Development Operations, Shire Pharmaceuticals, and conference chair, Dr Murray Abramson address in a fireside chat what it takes to develop strateg
1/20/18 - Arimoclomol for NPC receives Rare Pediatric Disease Designation [Arab Times (Kuwait)]
Orphazyme A/S, a Danish biotech company listed on Nasdaq Copenhagen, with a late-stage, orphan-drug pipeline, today announced that arimoclomol has been granted rare pediatric disease designation by the US Food and Drug Administration for the treatment of Niemann-Pick disease Type C. Arimoclomol has now been granted orphan drug, fast track, and rare
1/20/18 - Arvinas Announces Research Collaboration and License Agreement with Pfizer Inc. for the Discovery and Development of Protein Degradation Drug...
By a News Reporter-Staff News Editor at Marketing Weekly News Arvinas LLC, a private biotechnology company focused on creating a new class of drugs based on protein degradation, announced a research collaboration and license agreement with Pfizer Inc. for the discovery and development of drug candidates using Arvinas' proprietary PROTAC Platform,
1/20/18 - Avera To Enroll First Patients in Landmark Lung Cancer Tri-Therapy Clinical Trial [Sudan Tribune]
This clinical trial that received the approval of the FDA is Averas latest collaboration as part its membership in the Worldwide Innovative Networking Consortium. This latest step in our collaboration with WIN represents one clinical trial but is part of our larger goal to revolutionize cancer care through personalized medicine, said Benjamin Solom
1/20/18 - Biohaven to begin clinical development of BHV-5000 to treat Rett syndrome [Sport360]
Biohaven Pharmaceutical Holding Company Ltd. and its wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., announced that the US Food and Drug Administration has notified the company that it may proceed with its clinical investigation of BHV-5000. BHV-5000 is a low trapping, potent N-methyl-D-aspartate receptor antagonist licensed to Biohaven fr
1/20/18 - Clinical Trial Management Systems Market: Future Market Projections for Forthcoming Years
Albany, NY 01/19/2018 Lately, the global pediatric vaccination market has been exhibiting a robust growth. Various upcoming child healthcare programs by UNICEF and the WHO are likely to boost this market in the near future. North America, Europe, Asia Pacific, and the Rest of the World are the key regional markets for pediatric vaccines in th
1/20/18 - Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival in BRAF-Mutant Colorectal Cancer in Updated Safety Lead-In Results from BEACON Phase 3 Trial
BOULDER, Colo. and CASTRES, France, Jan. 20, 2018/ PRNewswire/ Array BioPharma Inc. and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients
1/20/18 - EC approves biosimilar bevacizumab for the treatment of certain types of cancer [Arab News (Saudi Arabia)]
Amgen and Allergan plc have that the European Commission has granted marketing authorisation for MVASI. The European Commissions approval of MVASI marks a significant milestone for both Amgen and the oncology community, providing a biosimilar for a medicine which is used across multiple types of cancer, said Sean E Harper, MD, executive vice presid
1/20/18 - Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Exelixis, Inc. today announced the presentation of updated results from the Genentech- sponsored phase 1 b clinical trial of cobimetinib, an Exelixis- discovered MEK inhibitor, in combination with atezolizumab, an anti-PDL1 antibody discovered and developed by Genentech, a member of the Roche Group, in patients with metastatic colorectal cancer.
1/20/18 - Lundbeck to test antidepressant on Korean teenagers [Arab Times (Kuwait)]
Lundbeck Korea said it would conduct a phase-3 clinical trial on antidepressant Brintellix for pediatric patients with a major depressive disorder in Korea. The Ministry of Food and Drug Safety recently approved the trial plan, which will assess the efficacy of Brintellix 10 mg, 15 mg, and 20 mg on 12 patients aged between 12 and 17.. Jointly devel
1/20/18 - Pandion Therapeutics Closes $58 Million Series A Round [Syrian Arab News Agency]
The company announced the closing of its $58 million Series A round of financing, co-led by Polaris Partners, the founding investor that provided the initial seed funding, Versant Ventures and Roche Venture Fund. The company, based in North Cambridge, Massachusetts, also announced key leadership appointments including CEO Anthony J. Coyle, PhD, and
1/20/18 - Pharmaceutical Outsourcing Market Research Report - Forecast 2016 - 2024: Pharmaceutical Outsourcing Market- Industry Value Forecast, Dynamics, growth, potential, segments, market share, Size, online PDF Report, Free Sample Copy, Future projection, A
New York, NY 01/19/2018 Pharmaceutical outsourcing, principally for contract research organization and contract manufacturing organizations, has developed during past ten years, and signs are that it will continue to develop over the forecast period. Complete new outsourcing industry sectors, like high-throughput screening services, have beco
1/20/18 - Popular morning sickness drug 'ineffective,' study reveals
In 2017, researchers working at the University of Toronto in Canada and the Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael's Hospital, also in Toronto, Canada, reanalyzed a pivotal doxylamine and pyridoxine clinical trial from the 1970 s and made a fairly surprising finding: the data had substantial flaws. Navindra Per
1/20/18 - Rocky start for Alzheimer`s drug research in 2018 [Arab Finance (Egypt)]
Within the first three weeks, pharmaceutical giant Pfizer abandoned the costly and frustrating field of dementia drug development, and two promising treatments stumbled in patient trials. Alzheimer`s support groups are putting on a brave face, but the collective disappointment is palpable as the global cost of caring for some 50 million dementia...
1/20/18 - X-Chem Enters Expanded Global Drug Discovery And Technology Transfer Collaboration With AstraZeneca [All Iraq News Agency (AIN)]
The new agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca as well as the transfer of the DEX platform, allowing for in-house screening of DNA-encoded libraries at AstraZeneca. It is the third agreement between AstraZeneca and X-Chem since 2012 and builds on the success of the parties existing collaboration, which ha
1/20/18 - Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018 [Tehran Times (Iran)]
Zealand receives FDA approval of its Investigational New Drug application for its Phase 3 program with dasiglucagon for treatment of congenital hyperinsulinism. Two Phase 3 trials are set to start within the coming months at leading centers in the U.S. and Europe. U.S. FDA and the European Commission have already granted orphan drug designation for
1/19/18 - "Combined Herbal and Pharmaceutical Composition and Method" in Patent Application Approval Process (USPTO 20170368124)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Syed, Uwais M., filed on June 27, 2016, was made available online on January 4, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institution. The followi
1/19/18 - 28 Stocks Moving In Friday's Mid-Day Session
Gainers Forward Industries, Inc. jumped 179 percent to $3.46 after the company reported the acquisition of Intelligent Product Solutions. NuCana PLC shares gained 43.6 percent to $20.81 as the company announced plans to initiate a Phase 3 study of Acelarin in front-line advanced biliary tract cancer. Bioblast Pharma Ltd. shares surged 24.1 percent
1/19/18 - 3rd Annual Clinical Trial Collaborations Event Comes to Boston in April 2018
The Conference Forum is pleased to announce the launch of the 3rd annual Clinical Trial Collaborations conference in Boston on April 9-11, 2018. Led by Co-Chairs Ken Getz, Director of Sponsored Research Programs, Tufts CSDD, and Murray Abramson, MD, VP Global Clinical Operations, Biogen, the CTC conference is a strategic-level event dedicated to co
1/19/18 - Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist
Adlai Nortye Biopharma Co., Ltd., a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement with Eisai Co., Ltd., a global pharmaceutical company with a focus on serving patients with unmet medical needs. Under the terms of the Agreeme
1/19/18 - Amarin Announces Commencement of VASCEPA Clinical Development in Mainland China
Amarin, a biopharmaceutical company focused on the commercialization and development of therapeutics, announced that a clinical trial of Vascepa capsules in a patient population with severe hypertriglyceridemia has been commenced in Mainland China, or China, by Amarin s partner, Eddingpharm. Similar to the MARINE trial conducted by Amarin, th
1/19/18 - Amgen And Allergan's MVASI Gets EU Approval To Treat Certain Types Of Cancer
THOUSAND OAKS- Amgen and Allergan plc. announced Thursday that the European Commission has granted marketing authorization for MVASI. Amgen and Allergan said they are committed to developing high-quality biosimilars with a robust analytic and clinical package. Amgen noted that MVASI is the first targeted cancer biosimilar from the company's portfol
1/19/18 - Anatomic Pathology: Latest Global Industry Research and Fast Growth in the Emerging Markets 2017-2024: Anatomic Pathology Market Type (Instruments {Tissue Processing Systems, Slide Staining Systems, Microtomes}, Consumables {Antibodies & Reagents, Ki
Pune, India 01/19/2018 The Global Anatomic Pathology Market accounted to USD 16.5 billion in 2016 growing at a CAGR of 6.5% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.. Market Definition: Global Anato
1/19/18 - Arimoclomol for NPC receives Rare Pediatric Disease Designation
Orphazyme A/S, a Danish biotech company, with a late-stage, orphan-drug pipeline, today announced that arimoclomol has been granted rare pediatric disease designation by the US Food and Drug Administration for the treatment of Niemann-Pick disease Type C. As quoted in the press release:. The post Arimoclomol for NPC receives Rare Pediatric Disease.
1/19/18 - Ascension, SSM partner to form generic drug company [St. Louis Post-Dispatch]
Utah- based Intermountain Healthcare is leading the collaboration that includes two St. Louis area health systems, Ascension and SSM Health, in addition to Michigan- based Trinity Health and the Department of Veterans Affairs. The generic drug company will either become an FDA- approved manufacturer or subcontract the work. One example of a pricey
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415